Ramon Andrade de Mello, ASCO 2019 – Immunotherapies in oesophageal and gastric cancer
At the ASCO 2019 annual meeting, Ramon Andrade de Mello discusses the promise of immunotherapies in oesophageal and gastric cancer. Highlighting the need to understand the tumor microenvironment to allow identification of biomarkers to appropriately select the best immune checkpoint inhibitors he also considers the role of combination therapy in improving overall outcomes.
1. What are the limitations of current immunotherapies in oesophageal and gastric cancer? (0:03)
2. How can we optimise the delivery of immunotherapy to overcome immunosuppression in the tumour microenvironment? (1:38)
3. What combined immunotherapy approaches appear most promising for oesophageal and gastric cancer? (2:51)
4. How can we select patients who are most likely to respond to combined immunotherapy approaches? (3:55)
5. What novel approaches are likely to emerge in the near future? (5:03)
Speaker disclosure: Ramon Andrade de Mello has received speaker honoraria from Novartis and AstraZeneca, an educational grant from Merck & Co and participated in advisory boards for MSD, Pfizer and Zodiac.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Gastrointestinal Cancers
Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer
Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]
Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer
Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!